Global Cancer Technology
[Closed for Investment] Global Cancer Technology is raising funds on Dalmore Group through Reg A+ crowdfunding. The company has acquired multiple patented technologies currently being tested as novel treatments for deadly diseases. The technology is presently focused on detecting and treating brain cancer and includes scintillating nanoparticles, cancer biomarkers, and cancer inhibitors. Global Cancer Technology is working with world-renowned scientists of the Barrow Neurological Institute, Baylor Scott & White Hospital, and the University of California San Diego. John P. Clark founded Global Cancer Technology in May 2017. The current crowdfunding campaign has no minimum target and a maximum target of $7,000,000. The campaign proceeds will be used for new product development, working capital, and general corporate purposes.
Investment Overview
Raised: $24,400
Deal Terms
Total Commitments ($USD)
- Platform
- Dalmore Group
- Start Date
- 09/08/2020
- Close Date
- Not Provided
$500
$7,000,000
$500
Equity - Common
RegA+
$2.00
Company & Team
Company
- Year Founded
- 2017
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Location
- San Diego, California
- Company Website
-
Visit Website
Team
- Employees
- 1
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/29/2022 | Netcapital | $26,682,636 | $0 | Equity - Common | Not Funded | RegCF |
| 09/08/2021 | Dalmore Group | - | $24,400 | Equity - Common | Funded | RegA+ |
| 02/25/2020 | Netcapital | $11,571,400 | $107,000 | Equity - Common | Funded | RegCF |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.